Core Viewpoint - Company is focusing on international expansion as a strategic initiative, leveraging the opportunity of "Chinese manufacturing" going global, and has successfully registered products in countries like Indonesia, Peru, and Mexico while accelerating certification processes in Turkey, Vietnam, and Brazil [1] Group 1: International Expansion - Company has established a global self-certification system to enhance its international market presence in the blood purification business, significantly improving its global competitiveness [1] - By the first half of 2025, the company achieved notable results in overseas market development, with overseas business revenue reaching 187 million yuan, representing a year-on-year growth of 67.30% [1] Group 2: Product Performance - Revenue from blood purification product exports reached 165 million yuan, accounting for 88% of total export revenue, with a year-on-year increase of 83.84% [1] - In the first half of 2025, export sales revenue of hemodialysis equipment grew by approximately 130%, while export sales revenue of hemodialysis consumables increased by about 70% [1] - The stable growth of key product exports has become a significant driver of the company's performance [1]

Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. reported a revenue of 761 million yuan in the first half of 2023, marking a year-on-year increase of 10.83%, with a net profit of 115 million yuan, up 8.35% year-on-year [2] Group 1: Financial Performance - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was 103 million yuan, reflecting a year-on-year growth of 9.26% [2] - Revenue from blood purification products reached 626 million yuan, representing a year-on-year increase of 19.73%, accounting for 82.23% of total revenue [3] - The gross margin for blood purification products was 34.30%, showing an increase compared to the previous year [4] Group 2: Market Expansion - The company achieved significant breakthroughs in overseas markets, with international sales revenue reaching 187 million yuan, a year-on-year increase of 67.30% [6] - Blood purification product exports contributed 165 million yuan to overseas sales, accounting for 88% of total export revenue, with an increase of 83.84% year-on-year [6] - The company is focusing on emerging markets along the "Belt and Road" initiative, which have large and growing populations, providing substantial market opportunities [6] Group 3: Industry Trends - The global end-stage renal disease (ESRD) patient population is projected to grow from 11.14 million in 2023 to 13.29 million by 2027, with a compound annual growth rate of 4.51% [3] - The demand for blood purification products is expected to remain strong due to the increasing number of ESRD patients and the essential nature of these products in treatment [4][3]

证券日报网讯三鑫医疗（300453）8月14日发布公告，在公司回答调研者提问时表示，公司不断加快国 际化进程，积极把握"中国智造"密集出海的历史机遇，成功完成印度尼西亚、秘鲁、墨西哥等国家的产 品注册，并加速推进土耳其、越南、巴西等市场的认证进程。截至报告期末，公司超百项产品已取得海 外注册证书，通过搭建全球自主持证体系，公司血液净化业务进一步强化国际市场布局，显著提升全球 竞争力，为品牌全球化奠定坚实基础。报告期内，海外市场开拓成效显著，海外业务实现营业收入18， 700.17万元，同比增长67.30%；其中：血液净化产品出口占出口总收入比重达88%，血液净化产品出口 销售收入1.65亿元，同比增长83.84%。报告期内，血液透析设备出口销售收入同比增长约130%，血液 透析耗材出口销售收入同比增长约70%。重点产品出口规模保持稳定增长，成为公司业绩增长的重要驱 动力。 ...

Core Viewpoint - The company is accelerating its internationalization process and capitalizing on the historical opportunity of "Chinese manufacturing" going global, achieving significant growth in overseas markets [1] Group 1: International Expansion - The company has successfully completed product registrations in Indonesia, Peru, and Mexico, and is advancing certification processes in Turkey, Vietnam, and Brazil [1] - Over 100 products have obtained overseas registration certificates, enhancing the company's global competitiveness and laying a solid foundation for brand globalization [1] Group 2: Financial Performance - Overseas business revenue reached 187 million yuan, representing a year-on-year growth of 67.30% [1] - Blood purification product exports accounted for 88% of total export revenue, with sales revenue of 165 million yuan, up 83.84% year-on-year [1] - Export sales revenue for blood dialysis equipment increased by approximately 130%, while sales revenue for blood dialysis consumables grew by about 70% [1] Group 3: Future Strategy - The company plans to accelerate the self-certification process in more countries and strengthen deep cooperation with key customers to further expand overseas markets [1]

Group 1 - The report provides a comprehensive overview of the blood dialysis consumables industry, including definitions, classifications, and regulatory frameworks [4] - It outlines the macro environment analysis of the blood dialysis consumables industry in China, focusing on policy, economic, social, and technological factors [5] - The report discusses the global development status and market trends of the blood dialysis consumables industry, including historical development and macro environment background [6] Group 2 - The impact of the COVID-19 pandemic on the global blood dialysis consumables industry is analyzed, highlighting changes in market dynamics [6] - The report examines the supply and demand conditions in the Chinese blood dialysis consumables market, identifying key pain points and trade status [6][7] - It includes a competitive landscape analysis of the Chinese blood dialysis consumables industry, assessing market concentration and competitive forces [7] Group 3 - The report details the investment and financing conditions within the Chinese blood dialysis consumables industry, including mergers and acquisitions [7] - It provides insights into the industry structure and value chain analysis, highlighting the roles of upstream suppliers and midstream market segments [8][9] - The report concludes with a market forecast and strategic investment recommendations for the blood dialysis consumables industry in China [10]